Peroxisome proliferator-activated receptor β/δ cross talks with e2f and attenuates mitosis in HRAS-expressing cells

Molecular and Cellular Biology

Volumn 32, Issue 11, 2012, Pages 2065-2082

  Zhu, Bokai ^a   Khozoie, Combiz ^a   Bility, Moses T ^a   Ferry, Christina H ^a   Blazanin, Nicholas ^a   Glick, Adam B ^a   Gonzalez, Frank J ^b   Peters, Jeffrey M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ANTIMITOTIC AGENT; CHECKPOINT KINASE 1; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; H RAS PROTEIN; HISTONE H2A; HISTONE H2AFZ; NOCODAZOLE; ONCOPROTEIN; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN P107; PROTEIN P130; PROTEIN SERINE THREONINE KINASE INHIBITOR; RO 3306; SB 218078; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL NUCLEUS; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HORMONE RECEPTOR INTERACTION; KERATINOCYTE; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; SARCOMA CELL; SIGNAL TRANSDUCTION; SKIN TUMOR; TRANSCRIPTION REGULATION; WILD TYPE;

ANIMALS; CELLS, CULTURED; E2F4 TRANSCRIPTION FACTOR; G2 PHASE CELL CYCLE CHECKPOINTS; KERATINOCYTES; MICE; MITOSIS; PPAR DELTA; PPAR-BETA; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION;

EID: 84864006355     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00092-12     Document Type: Article

References (70)

1. Akiyama TE, Meinke PT, Berger JP. 2005. PPAR ligands: potential therapies for metabolic syndrome. Curr. Diab. Rep. 5:45-52.
2. Balmain A, Ramsden M, Bowden GT, Smith J. 1984. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 307:658-660.
3. Bility MT, et al. 2008. Ligand activation of peroxisome proliferatoractivated receptor-β/δ (PPARβ/δ) inhibits chemically-induced skin tumorigenesis. Carcinogenesis 29:2406-2414.
4. Bility MT, Zhu B, Kang BH, Gonzalez FJ, Peters JM. 2010. Ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol. Sci. 113:27-36.
5. Bizub D, Wood AW, Skalka AM. 1986. Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc. Natl. Acad. Sci. U. S. A. 83:6048-6052.
6. Borland MG, et al. 2011. Stable over-expression of PPARβ/δ and PPAR_ to examine receptor signaling in human HaCaT keratinocytes. Cell Signal. 23:2039-2050.
7. Brown K, et al. 1986. v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis. Cell 46:447-456.
8. Carrassa L, Broggini M, Vikhanskaya F, Damia G. 2003. Characterization of the 5= flanking region of the human Chk1 gene: identification of E2F1 functional sites. Cell Cycle 2:604-609.
9. Chen HZ, Tsai SY, Leone G. 2009. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9:785-797.
10. Cheng L, Rossi F, Fang W, Mori T, Cobrinik D. 2000. Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16INK4A(-) tumor cells. J. Biol. Chem. 275:30317-30325.
11. Correa-Bordes J, Nurse P. 1995. p25rum1 orders S phase and mitosis by acting as an inhibitor of the p34cdc2 mitotic kinase. Cell 83:1001-1009.
12. Daya-Grosjean L, Robert C, Drougard C, Suarez H, Sarasin A. 1993. High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient xeroderma pigmentosum patients. Cancer Res. 53:1625-1629.
13. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, Yuspa SH. 1995. Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol. 254:3-20.
14. Do JH, Choi DK. 2006. Normalization of microarray data: single-labeled and dual-labeled arrays. Mol. Cells 22:254-261.
15. Fu M, et al. 2003. Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 315:33-41.
16. Fujita N, Wade PA. 2004. Use of bifunctional cross-linking reagents in mapping genomic distribution of chromatin remodeling complexes. Methods 33:81-85.
17. Genini D, Catapano CV. 2007. Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferatoractivated receptor _ activity. J. Biol. Chem. 282:11776-11785.
18. Girroir EE, et al. 2008. Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem. Biophys. Res. Commun. 371:456-461.
19. Greenhalgh DA, Welty DJ, Player A, Yuspa SH. 1990. Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 87:643-647.
20. Grimaldi PA. 2005. Regulatory role of peroxisome proliferator-activated receptor δ (PPARδ) in muscle metabolism. A new target for metabolic syndrome treatment? Biochimie 87:5-8.
21. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
22. Hansen K, et al. 2001. Phosphorylation-dependent and -independent functions of p130 cooperate to evoke a sustained G1 block. EMBO J. 20:422-432.
23. Hayles J, Fisher D, Woollard A, Nurse P. 1994. Temporal order of S phase and mitosis in fission yeast is determined by the state of the p34cdc2-mitotic B cyclin complex. Cell 78:813-822.
24. He P, et al. 2008. Effect of ligand activation of peroxisome proliferatoractivated receptor-β/δ (PPARβ/δ) in human lung cancer cell lines. Toxicology 254:112-117.
25. Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:44-57.
26. Ishida S, et al. 2001. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol. Cell. Biol. 21:4684-4699.
27. Itzhaki JE, Gilbert CS, Porter AC. 1997. Construction by gene targeting in human cells of a "conditional" CDC2 mutant that rereplicates its DNA. Nat. Genet. 15:258-265.
28. Jayadeva G, et al. 2010. B55_ PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation. J. Biol. Chem. 285:29863-29873.
29. Johnson DG, Ohtani K, Nevins JR. 1994. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8:1514-1525.
30. Kilgore KS, Billin AN. 2008. PPARβ/δ ligands as modulators of the inflammatory response. Curr. Opin. Invest. Drugs 9:463-469.
31. Kim DJ, et al. 2004. Peroxisome proliferator-activated receptor δ (δ)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem. 279:23719-23727.
32. Kim DJ, et al. 2006. PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13:53-60.
33. Kim DJ, et al. 2005. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem. 280:9519-9527.
34. Lee CH, Olson P, Evans RM. 2003. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201-2207.
35. Lee CH, et al. 2006. PPAR_ regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 103:3444-3449.
36. Luo J, et al. 2009. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848.
37. Malumbres M, Barbacid M. 2003. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3:459-465.
38. Moffat J, et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283-1298.
39. Mootha VK, et al. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34:267-273.
40. Moreno S, Nurse P. 1994. Regulation of progression through the G1 phase of the cell cycle by the rum1_ gene. Nature 367:236-242.
41. Müller H, et al. 2001. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 15:267-285.
42. Oliver WR, Jr, et al. 2001. A selective peroxisome proliferator-activated receptor _ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98:5306-5311.
43. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. 2009. Metabolic syndrome and risk of subsequent colorectal cancer. World J. Gastroenterol. 15:5141-5148.
44. Palkar PS, et al. 2010. Cellular and pharmacological selectivity of the PPARβ/δ antagonist GSK3787. Mol. Pharmacol. 78:419-430.
45. Peters JM, Foreman JE, Gonzalez FJ. 2011. Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast and lung carcinogenesis. Cancer Metastasis Rev. 30:619-640.
46. Peters JM, Gonzalez FJ. 2009. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim. Biophys. Acta 1796:230-241.
47. Peters JM, Hollingshead HE, Gonzalez FJ. 2008. Role of peroxisomeproliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin. Sci. (London) 115:107-127.
48. Peters JM, et al. 2000. Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferatoractivated receptor β/δ. Mol. Cell. Biol. 20:5119-5128.
49. Peters JM, Shah YM, Gonzales FJ. 2012. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat. Rev. Cancer 12:181-195.
50. Peters JM, Morales JL, Gonzales FJ. 2011. Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferatoractivated receptor-β/δ (PPARβ/δ). Drug Discov. Today 8:e85- e93.
51. Prizment AE, Flood A, Anderson KE, Folsom AR. 2010. Survival of women with colon cancer in relation to precancer anthropometric characteristics: the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev. 19:2229-2237.
52. Ren B, et al. 2002. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 16:245-256.
53. Roop DR, et al. 1986. An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 323:822-824.
54. Schadt EE. 2009. Molecular networks as sensors and drivers of common human diseases. Nature 461:218-223.
55. Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7:295-308.
56. Strickland JE, et al. 1988. Development of murine epidermal cell lines which contain an activated rasHa oncogene and form papillomas in skin grafts on athymic nude mouse hosts. Cancer Res. 48:165-169.
57. Subramanian A, et al. 2005. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102:15545-15550.
58. Svaren J, et al. 2000. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J. Biol. Chem. 275:38524-38531.
59. Terzić J, Grivennikov S, Karin E, Karin M. 2010. Inflammation and colon cancer. Gastroenterology 138:2101-2114. e2105.
60. Tsugane S, Inoue M. 2010. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 101:1073-1079.
61. Westergaard M, et al. 2001. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. 116:702-712.
62. Wolin KY, Carson K, Colditz GA. 2010. Obesity and cancer. Oncologist 15:556-565.
63. Xu X, et al. 2007. A comprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members. Genome Res. 17:1550-1561.
64. Yang L, et al. 2011. Biological function and prognostic significance of peroxisome proliferator-activated receptor _ in rectal cancer. Clin. Cancer Res. 17:3760-3770.
65. Yuspa SH, Morgan DL. 1981. Mouse skin cells resistant to terminal differentiation associated with initiation of carcinogenesis. Nature 293: 72-74.
66. Zachos G, et al. 2007. Chk1 is required for spindle checkpoint function. Dev. Cell 12:247-260.
67. Zanet J, et al. 2010. A mitosis block links active cell cycle with human epidermal differentiation and results in endoreplication. PLoS One 5:e15701.
68. Zhu B, et al. 2010. Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase 2. Mol. Cancer Ther. 9:3267-3277.
69. Zhu L, et al. 1993. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev. 7:1111-1125.
70. Zhu W, Giangrande PH, Nevins JR. 2004. E2Fs link the control of G1/S and G2/M transcription. EMBO J. 23:4615-4626.